Ernexa's ERNA-101 Clears Key Safety Hurdles, IND Filing Set for Q4
ERNA sits 16% above its 52-week low of $3.044 on light trading volume (0.1× avg).
Summary
Ernexa reported clean safety data from three IND-enabling studies for its lead cell therapy ERNA-101: no adverse findings in repeat-dose GLP toxicology, no teratomas through six-month tumorigenicity in-life phase, and no significant biodistribution signal outside tumors. These results address the main safety questions for an iPSC-derived therapy and support the tumor-homing design. The company says GMP manufacturing is underway and it remains on track to submit an IND in Q4 2026 for platinum-resistant ovarian cancer, with initial clinical data expected Q4 2027. This follows earlier preclinical efficacy data showing complete tumor clearance and durable survival in ovarian cancer models. The news is a meaningful de-risking event for a micro-cap biotech with only $5M in cash, but the IND submission itself is still months away and clinical proof is years out.
At the time of this announcement, ERNA was trading at $3.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $3.04 to $71.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.